| Dapirolizumab pegol | Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133 | Phase 3 Clinical | Biogen Inc, Ucb | Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases | Details |
| Dazodalibep | VIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399 | Phase 3 Clinical | Horizon Therapeutics PLC, Medimmune Llc | Arthritis, Rheumatoid; Graft Rejection; Lupus Nephritis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome | Details |
| Frexalimab | INX-021; SAR-441344 | Phase 3 Clinical | Immunext Inc | Diabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Multiple Sclerosis; Nephrosis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome | Details |
| Anti-CD40L antibody (Bristol-Myers Squibb) | | Phase 2 Clinical | Bristol-Myers Squibb Company | Immunologic Deficiency Syndromes | Details |
| Tegoprubart | AT-1501 | Phase 2 Clinical | Als Therapy Development Institute | Amyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 1; Glomerulonephritis, IGA; Rejection of renal transplantation | Details |
| Delolimogene mupadenorepvec | LOAd-703 | Phase 2 Clinical | Lokon Pharma, Uppsala University | Biliary Tract Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms | Details |
| TNX-1500 | TNX-1500 | Phase 2 Clinical | Tonix Pharmaceuticals Holding Corp | Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Rejection of renal transplantation; Rejection of organ transplantation | Details |
| Base-edited hematopoietic stem and progenitor cells therapy (NIAID) | | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | Hyper-IgM Immunodeficiency Syndrome, Type 1 | Details |
| CD40 ligand expressing MSLN-CAR T cells | | Phase 2 Clinical | Pla General Hospital | | Details |
| Letolizumab | BMS-986004; BMS2h-572-633-CT-L2 | Phase 1 Clinical | Bristol-Myers Squibb Company | Graft vs Host Disease; Purpura, Thrombocytopenic, Idiopathic | Details |
| MEM-288 | MEM-288 | Phase 1 Clinical | Memgen | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IBI355 | IBI-355 | Phase 1 Clinical | | Lupus Erythematosus, Systemic; Sjogren's Syndrome | Details |
| CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute) | | Phase 1 Clinical | H Lee Moffitt Cancer Center & Research Institute | Carcinoma, Non-Small-Cell Lung | Details |
| Lu-AG22515 | APB-A1; Lu-AG22515 | Phase 1 Clinical | AprilBio Co Ltd | Graves Ophthalmopathy; Neuromyelitis Optica | Details |
